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Abstract HIV-gpl20 sensitizes Thl clones from seronegative 
donors to apoptosis, which occurs through two distinct events: 
expression of CD95L followed by its interaction with CD95 to 
trigger cell death. gpl20-apoptosis of the Thl clone 103 was 
inhibited by Cyclosporin A, the PTK inhibitors Genistein and 
PNU152518, as well as the anti-oxidants Ascorbic Acid and 
Glutathione. Cyclosporin A interfered with CD95L expression, 
Ascorbic Acid and Glutathione inhibited cell death triggered by 
CD95/CD95L interaction; Genistein and PNU152518 acted on 
both steps. The occurrence of oxidative stress during CD95-
dependent apoptosis was supported by the direct evidence of ROI 
production. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
We have previously reported [1] that, following HIV-gpl20/ 
CD4 cross-linking and CD3/TCR activation, a human Thl 
clone (clone 103) from an HIV-seronegative donor underwent 
apoptosis (thereafter indicated as gpl20-apoptosis). In this 
system, either gpl20/CD4 cross-linking or CD3/TCR stimula-
tion alone did not induce relevant cell death. These observa-
tions were consistent with results obtained by others using 
polyclonal CD4+ populations and suggested that apoptosis 
of uninfected CD4+ cells could contribute to CD4+ lympho-
cyte depletion in AIDS patients [2]. The CD95 (Fas/APO-1)/ 
CD95L (Fas-L) cell death pathway was related to AIDS 
pathogenesis as suggested by the increased CD95 expression 
and increased susceptibility to CD95-mediated apoptosis ob-
served on T lymphocytes from HIV-infected individuals [3-5]. 
More recently [6], we obtained evidence for a differential 
susceptibility of Thl and Th2 clones to gpl20-apoptosis de-
pending on different expression of CD95L, which is upregu-
lated in Thl but not Th2 clones. A two-step model for gpl20-
apoptosis in Thl clones could be formulated: treatment with 
gpl20/anti-gpl20/anti-TCR induces significant expression of 
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membrane-anchored and soluble functional CD95L (step 1); 
the subsequent interaction (in autocrine or paracrine fashion) 
of CD95L with its receptor, CD95, triggers cell death (step 2). 
The aim of the present work was to identify agents able to 
rescue Thl clones from gpl20-apoptosis, interfering with ei-
ther step 1 or step 2. Several different potential inhibitors, 
chosen because effective in other models of apoptosis [7], 
were tested. 
Cyclosporin A is an immunosuppressant affecting the cal-
modulin/calcineurin signal transduction pathway and already 
known to block activation-induced cell death by interfering 
with CD95L induction [8,9]; thus, it was expected to inhibit 
gpl20-apoptosis, which represents a form of activation-in-
duced cell death [6]. 
Genistein is a natural, broad spectrum inhibitor of PTKs 
[10], whereas PNU152518, previously named TMO [11] or 
FCE26806 [1,12], is a PTK inhibitor with a more restricted 
activity, known to block Met [11] and Abl [12]. The involve-
ment of PTKs in TCR-dependent signal transduction and in 
apoptosis has been shown in a variety of systems [7], but there 
is not general consensus on whether they are required for 
CD95-mediated apoptosis [13-19]. 
The involvement of oxidative injure in apoptosis has been 
reported in various models [20] and the water-soluble anti-
oxidants Ascorbic acid and Glutathione are known to block 
some forms of apoptotic cell death [7]. Nonetheless, the role 
of oxidative stress in CD95-mediated cell death is still debated 
[15,21-27]. 
After identification of agents blocking gpl20-apoptosis, we 
determined which of them act by inhibiting induction of func-
tional CD95L and which act downstream the triggering of 
CD95. 
Inhibition of CD95-mediated death in our Thl clone by 
anti-oxidants indicated a role for oxidative damage down-
stream CD95 triggering. To confirm this hypothesis, the gen-
eration of ROI following CD95 crosslinking was directly in-
dagated. 
Our data could contribute to the comprehension of cellular 
mechanisms involved in gpl20-apoptosis, as well as suggest 
the use of anti-oxidants as adjuvants in therapeutic strategies 
aimed at counteracting the depletion of uninfected CD4+ lym-
phocytes during AIDS progression. 
2. Materials and methods 
2.1. Cells 
Clone 103, a human CD3+ CD4+ Thl clone, has been previously 
described [1]. It was cultured at 37°C in a 5% CO2 atmosphere, in 
complete medium composed of RPMI 1640 (MA Bioproducts, Wal-
kersville, MD) supplemented with 2 mM glutamine (MA Bioprod-
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
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ucts), 20 mM HEPES buffer (MA Bioproducts), 100 U/ml penicillin 
and 100 |ig/ml streptomycin (Pharmacia, Milan, Italy) plus 10% 
pooled human heat-inactivated serum. IL-2 (Proleukin, Eurocetus, 
Amsterdam, The Netherlands) was added at a final concentration of 
180 IU/ml. Clone 103 cells (2xl05/well) were cultured in 24 well 
plates (Costar, Cambridge, MA) and weekly restimulated with irradi-
ated allogeneic PBL (4 x10 s cells/well) and 1 (ig/ml PHA (Murex, 
Temple Hile Dartford, UK). 
Six days after the last restimulation, cells were washed twice with 
medium, then used in experiments. 
was used. Cells (105/sample in 0.1 ml medium) were loaded with 1 U.M 
DHR (30' at 37°C), then treated with 1 ug/ml agonistic anti-CD95 
mAb CH-11 or with 100 nM H 2 0 2 , respectively. Samples were har-
vested at the indicated times and immediately analyzed (5000 cells/ 
sample) by FACScan. 
For inhibition experiments, neutralizing anti-CD95 mAb ZB4 (50 
ng/ml) or Glutathione (500 (ig/ml) were added during DHR loading 
(30' at 37°C), then maintained throughout all phases of the assay. 
Generation of ROI was revealed by an increase in MFI. 
2.2. mAbs 
The following mAbs were used: BMA031 (anti-TCR); CH-11 (anti-
CD95 IgM, apoptosis inducing), ZB4 (anti-CD95 IgGl, neutralizing) 
(both from MBL Co., Nagaya, Japan); anti-gpl20 (HIV-1) (Intracel, 
London, UK). Suitable isotype-matched controls (Cymbus Bioscience 
LTD, Southampton, Hants., UK) were employed. 
2.3. Induction of apoptosis 
2.3.1. gpl20 protocol. 107 cells/ml were treated with recombinant 
HIV-1 gpl20 (Intracel, London, UK) (10 ng/ml, 30' at 37°C), washed 
once, then treated with mouse anti-gpl20 (HIV-1) mAb (10 |xg/ml, 30' 
at 4°C), washed once and seeded (106 cells/w) in 48 well plates coated 
with anti-TCR mAb (BMA031, 5 ng/ml in PBS, 1 h at 37°C). After 
4 h, apoptosis was evaluated by TUNEL [1,6] and confirmed by 
propidium iodide staining and morphological analysis. Net % 
gpl20-apoptosis was calculated as: % apoptotic cells after induction 
(gpl20/anti-gpl20/immobilized anti-TCR)—% apoptotic cells after ac-
tivation (immobilized anti-TCR only). Positive and negative controls 
for apoptosis were irradiated cells (10000 Rad) and cells maintained 
in IL-2 (180 IU/ml), respectively (not shown). 
2.3.2. Anti-CD95 protocol. 10e cells/well were seeded in 48 well 
plates (Costar, Cambridge, MA) and cultured in the presence of dif-
ferent doses of agonistic anti-CD95 mAb CH-11. After 4 h, apoptosis 
was evaluated as described for gpl20-protocol. Net % anti-CD95-
apoptosis was calculated as: % apoptotic cells in the presence of 
CH-11—% apoptotic cells in medium only. 
2.4. Inhibition of apoptosis 
For inhibition experiments, cells (107/ml) were pre-treated for 30' at 
37°C with medium only or with the following agents, at doses pre-
viously determined to be non-cytotoxic (not shown): Cyclosporin A 
(Sandimmun, Sandoz AG, Basel, Switzerland) (50 ng/ml), Genistein 
(Calbiochem, San Diego, CA) (10 nM), PNU152518 (Pharmacia and 
Upjohn, Milan, Italy) (10 nM), L-Ascorbic Acid (Sigma Chemical Co, 
St. Louis, MO) (500 nM) or Glutathione (Tationil, Boehringer Mann-
heim Italia, Milan, Italy) (500 [iglrai). Apoptosis was then induced 
following gpl20 or anti-CD95 protocol. Inhibitors were maintained 
(at the same doses used for pre-treatment) throughout all passages of 
apoptosis induction and culture. 
For each experiment, relative % gpl20-apoptosis or anti-CD95-
apoptosis in the presence of any given inhibitor was calculated as 
follows: [(% apoptosis with inhibitor/% apoptosis without inhibi-
tor) X100]. 
2.5. Assay for functional CD95L 
Functional CD95L expression was evaluated as previously de-
scribed [6]. Briefly, clone 103 cells were pre-treated with 1 ng/ml n o -
tarizing anti-CD95 mAb ZB4 (30' incubation on ice, then extensively 
washed) to prevent possible CD95L sequestration by CD95 receptors 
on the surface of the producing cells, then cultured for 1 h following 
the protocol for induction of gpl20-apoptosis. Cells were then col-
lected, washed and used as effectors in 16 h 51Cr release assay against 
CD95+ Jurkat cells (E/T = 2). The assay was performed in triplicate. 
For inhibition experiments, cells were treated with inhibitors (same 
doses used for apoptosis experiments) 30' at 37°C prior to CD95L 
induction. 
2.6. Measure of endocellular ROI 
DHR (Molecular Probes, Eugene, OR) was used to detect the pro-
duction of ROI. The fluorescence of this cell-permeable probe is sig-
nificantly increased after oxidation, particularly by hydroperoxides 
[28]; the oxidized form, rhodamine-123, is sequestered by active mi-
tochondria and is not subjected to significant leakage from cells main-
tained at 37°C. A modification of a previously published protocol [29] 
3. Results 
3.1. Effect of various agents on gp!20-apoptosis 
A representative experiment showing gpl20-apoptosis and 
apoptosis induced by agonistic anti-CD95 m A b is reported in 
Fig. 1A and B, respectively. A series of potential cell death 
inhibitors were screened for in vitro effects on gpl20-apopto-
sis (Fig. 2A). gpl20-apoptosis was prevented by the immuno-
suppressive drug Cyclosporin A, by the PTK inhibitors Gen-
istein and PNU152518, as well as by the anti-oxidant agents 
Ascorbic Acid and Glutathione. As already reported [6], 
gpl20-apoptosis was also efficiently inhibited by the neutraliz-
ing anti-CD95 m A b ZB4, a finding consistent with the in-
volvement of CD95/CD95L interaction. 
3.2. Effect of inhibitors of gpl20-apoptosis on functional 
CD95L expression 
We then assessed whether agents able to inhibit gp l20-
apoptosis could block induction of CD95L. Functional 
CD95L was detected by 51Cr-release assay on CD95+ Jurkat 
cells (Fig. 2B). T h l cells treated for gpl20-apoptosis had sig-
nificantly higher lytic activity than cells cultured with anti-
T C R only (Fig. 2B) or in medium only (not shown). The lysis 
was CD95-dependent, as it was inhibited by the neutralizing 
anti-CD95 m A b ZB4, but not by an irrelevant isotype-
matched control ([6] and data not shown); moreover, in the 
same experiment, no lytic activity was seen against the C D 9 5 " 
cell line K562 (not shown). A significant decrease of gp l20-
induced lytic activity was observed in the presence of the 
immunosuppressive drug Cyclosporin A, known to block 
CD95L induction in other systems [8,9], as well as with the 
PTK inhibitors Genistein and PNU152518. 
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Fig. 1. Apoptosis induced in a Thl clone by gpl20 (A) or by ago-
nistic anti-CD95 mAb CH-11 (B). Clone 103 was cultured in me-
dium, activated with immobilized anti-TCR or treated for gpl20-
apoptosis (A); alternatively, it was seeded in the presence of the in-
dicated doses of agonistic anti-CD95 mAb CH-11 (B). After 4 h, 
apoptosis was evaluated by TUNEL. At time 0, apoptotic cells were 
2%. 
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Fig. 2. Effect of various agents on gpl 20-apoptosis, functional CD95L expression and anti-CD95-apoptosis. (A) Clone 103 was treated for 
gpl 20-apoptosis in medium only or in the presence of the indicated agents. After 4 h, apoptosis was evaluated by TUNEL. Data are expressed 
as relative % gpl 20-apoptosis (meaniS.D. from at least three independent experiments). Net gpl 20-apoptosis in the absence of inhibitors was 
17±5% (meantS.D. from 7 independent experiments). (B) Thl clone 103 was activated with anti-TCR only or treated for the induction of 
gpl 20-apoptosis in medium only or in the presence of the indicated agents. After 1 h, cells were collected, washed and tested in a 16 h 51Cr-re-
lease assay against labelled CD95+ Jurkat cells. * P<0 .05 (Student's /-test). (C) Clone 103 was treated with 1 ug/ml agonistic anti-CD95 mAb 
CH-11 in medium only or in the presence of the indicated agents. After 4 h, apoptosis was evaluated by TUNEL. Data are expressed as rela-
tive % anti-CD95-apoptosis (mean ± S.D. from at least three independent experiments). Net anti-CD95-induced apoptosis in the absence of in-
hibitors was 30± 15% (meaniS.D. from 5 independent experiments). 
3.3. Effect of inhibitors of gpl 20-apoptosis on cell death 
triggered by agonistic anti-CD95 mAb 
To test which inhibitors of gpl 20-apoptosis act downstream 
CD95L/CD95 interaction, agonistic anti-CD95 mAb was used 
to induce cell death (Fig. 2C). Apoptosis was blocked by the 
PTK inhibitors Genistein and PNU152518 as well as by the 
anti-oxidants Glutathione and Ascorbic Acid but not by Cy-
dosporin A. As expected [6], the neutralizing anti-CD95 mAb 
ZB4 also prevented cell death. 
In summary, our results indicate that Cydosporin A inhib-
its gpl 20-apoptosis by interfering with CD95L induction, As-
corbic Acid and Glutathione by interfering with the effector 
phase downstream CD95 triggering; Genistein and 
PNU152518 act on both steps. 
3.4. Generation of ROI following CD95 triggering 
To directly prove the generation of ROI downstream CD95 
cross-linking the cell-permeable probe DHR was used (Fig. 3). 
An increase in MFI, indicative of ROI generation, was evi-
dent after direct triggering of CD95 receptor by agonistic anti-
CD95 mAb CH-11. This MFI shift was prevented by either 
addition of the neutralizing anti-CD95 mAb ZB4 or the anti-
oxidant Glutathione. As a positive control for oxidative stress, 
cells were treated with H 2 0 2 ; as expected, the observed in-
crease in MFI was prevented by Glutathione, but not by ZB4. 
Similar results were obtained from 3 independent experiments. 
The MFI shift induced by either CH-11 or H 2 0 2 was also 
inhibited by Ascorbic Acid (not shown). A significant increase 
in MFI was also seen following treatment with recombinant 
human CD95L (not shown). 
Fig. 4 shows a time-course experiment in which ROI were 
detected as soon as 90' after CD95 triggering, peaked at 3 h 
and then remained elevated up to 20 h. To further support the 
hypothesis that generation of ROI was linked to cell death, 
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Fig. 3. Endocellular generation of ROI. Cells were loaded with DHR, then treated with 1 ug/ml agonistic anti-CD95 mAb CH-11 (left panels) 
or 100 uM H202 (right panels). After 3 h, they were collected and analyzed by FACScan. The experiment was performed in medium only (—) 
and in the presence of 50 ng/ml neutralizing anti-CD95 mAb ZB4 or 500 ug/ml Glutathione. Cells treated with CH-11 or H2O2 (closed areas) 
were compared with the corresponding untreated cells (open areas). 
the presence of apoptotic cells was scored along with DHR 
fluorescence on the same sample at the indicated time points. 
Apoptosis was indeed increasing up to 20 h. 
4. Discussion 
Apoptosis of uninfected CD4+ lymphocytes participates in 
AIDS progression and a variety of in vitro models have been 
developed to investigate the potential mechanisms involved in 
this phenomenon [2]. gpl20-apoptosis (resulting from treat-
ment with gpl20/anti-gpl20 mAb and immobilized anti-
TCR or -CD3 mAb) could be detected on isolated CD4+ 
lymphocytes [2] as well as on CD4+ Thl clones [1,6] from 
HIV-seronegative donors. We recently reported [6] that Thl 
but not Th2 clones are highly susceptible to gpl20-apoptosis 
and that this differential sensitivity depends on different ex-
pression of CD95L, which is upregulated in Thl but not Th2 
cells. 
In Thl clones, gpl20-apoptosis can be regarded as a two 
step phenomenon: treatment with gpl20/anti-gpl20/anti-TCR 
induces CD95L expression (step 1); then, interaction between 
CD95L and its receptor, CD95, triggers cell death (step 2). 
This model is consistent with the hypothesis that gpl20-apop-
tosis could represent a form of activation-induced cell death 
2 
< 
8. 
time (h) 
Fig. 4. Kinetics of ROI generation and cell death following CD95 triggering. Cells were loaded with DHR, treated with 1 ug/ml agonistic anti-
CD95 mAb CH-11, collected at the indicated times and analyzed by FACScan. Data are expressed as AMFI=MFI of treated cells—MFI of un-
treated cells at the same time point. % anti-CD95-apoptosis was evaluated on the same samples, on the basis of low FSC-H/high SSC-H char-
acteristics of apoptotic cells. 
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[6], a physiologic phenomenon involved in peripheral cell se-
lection and immune response regulation and clearly dependent 
on CD95L/CD95 interaction [30]. 
CD95-mediated apoptosis has been extensively studied in a 
variety of systems and a detailed model for signal transduc-
tion has been proposed, based on the knowledge of adaptor 
molecules and proteolytic enzymes activated downstream 
CD95 triggering [30]. However, some aspects, such as the 
role of protein tyrosine phosphorylation [13-19] as well of 
oxidative stress [15,21-27], remain controversial. The present 
work was aimed at studying the effect of PTK inhibitors, anti-
oxidants and Cyclosporin A on gpl20-apoptosis of Thl 
clones. 
In our system, Cyclosporin A was able to block gpl20-
apoptosis (Fig. 2A). The finding that this immunosuppressant 
interferes with CD95L induction (step 1, Fig. 2B) rather than 
with the effector phase downstream CD95 triggering (step 2, 
Fig. 2C) suggested that signal transduction through the cal-
modulin/calcineurin pathway should be required for gpl20-
induced CD95L expression. This was in agreement with the 
observation that Cyclosporin A blocks activation-induced 
apoptosis by interfering with CD95L expression [8,9]. The 
efficacy of Cyclosporin A in inhibiting gpl20-apoptosis could 
add a new rationale for its therapeutic use in AIDS, since it 
has already been proposed on the basis of other observations 
such as the inhibition of HIV replication in vitro and the 
delay of AIDS onset in HIV-infected patients treated with 
Cyclosporin A [31]. 
The role of PTKs in apoptosis has been suggested in a 
variety of systems [7]. Here we show that both the broad-
spectrum inhibitor Genistein [10] and the more specific agent 
PNU 152518 [1,11,12] interfere with both steps of gpl20-
apoptosis. The finding that the activity of one or more 
PTKs may be required for CD95L induction is consistent 
with the relevance of tyrosine phosphorylation in TCR signal-
ling [32], whereas the role of PTKs in apoptosis initiated by 
CD95 triggering is still controversial. Some studies have 
shown that, in the Jurkat T cell line, CD95-mediated apopto-
sis is not affected by PTK inhibitors [14,15] and does not 
imply protein tyrosine phosphorylation [14,16]; moreover, evi-
dence that PTKs such as Abl could have an anti-apoptotic 
effect has recently been reported [33]. On the contrary, other 
studies have shown that PTKs participate in CD95-dependent 
early signalling events [13,17-19]. Our data, obtained in a 
normal Thl clone, are clearly in agreement with these last 
results. Although further work is needed to identify the spe-
cific PTKs involved in gpl20-apoptosis, the possibility of us-
ing PTK inhibitors for AIDS therapy is attractive, since they 
could reduce CD4+ cell apoptosis as well as interfere with 
virus replication [34] and its cytopathic effect [35]. 
Oxidative stress has also a role in AIDS pathogenesis [20]. 
HIV-infected individuals exhibit systemic Glutathione defi-
ciencies [36-38] and redox balance alterations in their CD4+ 
lymphocytes [39,40]. Although oxidative stress is a relevant 
step in many models of apoptosis [20], its role in CD95-medi-
ated apoptosis is still debated. Studies addressing this aspect 
in monocytes [27] and T cell leukemia cells [25,26] have shown 
that oxidative injure is part of CD95-dependent apoptosis. On 
the contrary, studies performed on murine L929 fibroblasts 
expressing human CD95 [21,22], CD95-sensitive human mel-
anoma [24] and lymphoid cell lines [23,24], presented contrast-
ing evidence. 
Here we show that the anti-oxidants Ascorbic Acid and 
Glutathione efficiently block gpl20-apoptosis of our Thl 
clone downstream CD95 triggering, a result consistent with 
the involvement of oxidative stress in this cell death pathway. 
The possibility that Glutathione may block CD95-mediated 
cell death by decreasing CD95 expression [41] has been ex-
cluded, as no differences were observed between untreated and 
inhibitor-treated cells (data not shown). 
Moreover, we present a direct evidence that CD95-initiated 
apoptosis in Thl lymphocytes involves generation of ROI 
(Figs. 3 and 4), a finding previously reported for monocytes 
[27] and adult T leukemia cells [26] but not for normal T 
lymphocytes. 
These results should give strength to the rationale for ther-
apeutic use of anti-oxidants in AIDS [42]. 
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